Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan - PubMed

4 hours ago

Finerenone shows promise in reducing albuminuria in diabetic kidney disease patients on maximal doses of dapagliflozin and telmisartan.
In this retrospective study, finerenone led to a 9.5% mean reduction in urinary albumin-to-creatinine ratio, with 66.7% of patients responding.
Treatment response varied by baseline albuminuria, with greater proportional reductions seen in patients with lower baseline levels.
Finerenone was generally well tolerated, with mild hyperkalemia occurring in 15.2% of patients, but no treatment discontinuations were required.
The findings support using finerenone as add-on therapy in a multimodal strategy for managing proteinuria in diabetic kidney disease.

Hasty Briefsbeta